Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
Giovanna Carrà, Antonio Cartellà, Beatrice Maffeo, Alessandro Morotti Department Of Clinical And Biological Sciences, University Of Turin, Orbassano 10043, ItalyCorrespondence: Alessandro MorottiDepartment Of Clinical And Biological Sciences, University Of Turin, Regione Gonzol...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d6b035faa8974ec89b243aab7d01bf27 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Giovanna Carrà, Antonio Cartellà, Beatrice Maffeo, Alessandro Morotti Department Of Clinical And Biological Sciences, University Of Turin, Orbassano 10043, ItalyCorrespondence: Alessandro MorottiDepartment Of Clinical And Biological Sciences, University Of Turin, Regione Gonzole 10, Orbassano 10043, ItalyEmail alessandro.morotti@unito.itAbstract: Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.Keywords: chronic myeloid leukaemia, stem cells, tyrosine kinase inhibitors |
|---|